Numbers of early CD34+ progenitors of bone marrow hematopoiesis in patients with diffuse large B-cell lymphoma
- Authors: Dorokhina EI1, Magomedova AU1, Galtseva IV1, Dvirnyk VN1, Glinkina SA1, Kulikov SM1, Kravchenko SK1
-
Affiliations:
- Гематологический научный центр Минздрава России
- Issue: Vol 89, No 1 (2017)
- Pages: 43-48
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32182
- DOI: https://doi.org/10.17116/terarkh201789143-48
- ID: 32182
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
E I Dorokhina
Гематологический научный центр Минздрава РоссииМосква, Россия
A U Magomedova
Гематологический научный центр Минздрава РоссииМосква, Россия
I V Galtseva
Гематологический научный центр Минздрава РоссииМосква, Россия
V N Dvirnyk
Гематологический научный центр Минздрава РоссииМосква, Россия
S A Glinkina
Гематологический научный центр Минздрава РоссииМосква, Россия
S M Kulikov
Гематологический научный центр Минздрава РоссииМосква, Россия
S K Kravchenko
Гематологический научный центр Минздрава РоссииМосква, Россия
References
- Магомедова А.У., Кравченко С.К., Кременецкая А.М., Звонков Е.А., Барях Е.А., Мангасарова Я.К., Воробьев А.И. Девятилетний опыт лечения больных диффузной В-крупно-клеточной лимфосаркомой. Тер. архив. 2011;7:5-10.
- Магомедова А.У. Диффузная В-крупноклеточная лимфосаркома лимфоидных органов: клинические формы и лечение: Дис. д-ра мед. наук. М.; 2008.
- Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040-2045. doi: 10.1182/blood-2010-03-276246
- Pfreundschuh M, Kuhnt E, Trumper L et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013-1022. doi: 10.1016/s1470-2045(11)70235-2
- Récher C, Coiffier B, Haioun C, Molina T, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais J, Salles G, Tilly H. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858-1867. doi: 10.1016/s0140-6736 (11)61040-4
- Neben S, Hellman S, Montgomery M, Ferrara J, Mauch P, Hemman S. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol. 1993;21(1):156-162.
- To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997;89(7):2233-2258.
- Gordon MY. Physiology and function of the haemopoietic microenvironment. Br J Haematol. 1994;86(2):241-243.
- Hays K. Physiology of normal bone marrow. Semin Oncol Nurs. 1990;6(1):3-8.
- Parchment RE, Gordon M, Grieshaber CK, et al. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol. 1998;9(4):357-364.
- Smith C. Hematopoietic stem cells and hematopoiesis. Cancer Control. 2003;10(1):9-16.
- Travlos GS. Normal structure, function, and histology of the bone marrow. Toxicol Pathol. 2006;34 (5):548-565.132. doi: 10.1080/01926230600939856
- Snoeck HW. Aging of the hematopoietic system. Curr Opin Hematol. 2013;20(4):355-361. doi: 10.1097/moh.0b013e3283623c77
- Fliedner TM, Graessle D, Paulsen C, Reimers K. Structure and function of bone marrow hemopoiesis: mechanisms of response to ionizing radiation exposure. Cancer Biother Radiopharm. 2002; 17(4):405-426. doi: 10.1089/108497802760363204
- Shen Y, Nilsson SK. Bone, microenvironment and hematopoiesis. Curr Opin Hematol. 2012;19(4):250-255. doi: 10.1097/moh.0b013e328353c714
- Gale R. Antineoplastic chemotherapy myelosuppression: Mechanisms and new approaches (Keynote address). Exp Hematol. 1985;13:3-7.
- O´Flaherty E, Sparrow R, Szer J. Bone marrow stromal function from patients after bone marrow transplantation. Bone Marrow Transplant. 1995;15:207-212.
- Minderman H, Linssen P, van der Lely N, Wessels J, Boezeman J, de Witte T, Haanen C. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia. 1994;8(3):382-387.
- Schein PS, Winokur SH. Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann Intern Med. 1975;82(1):84-95.
- Trainor KJ, Seshadri RS, Morley AA. Residual marrow injury following cytotoxic drugs. Leuk Res. 1979;3(4):205-210.
- Lohrmann HP. The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology. 1984;41(3):180-184.
- Brooimans RA, Kraan J, Putten W, Cornelissen JJ, Lo¨wenberg B, and Gratama1 JW. Flow Cytometric Differential of Leukocyte Populations in Normal Bone Marrow: Influence of Peripheral Blood Contamination. Cytometry Part B (Clinical Cytometry). 2009;76B:18-26. doi: 10.1002/cyto.b.20439
- Ширин А.Д., Френкель М.А. Современная диагностика миелодиспластических синдромов взрослых. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2010;3(3).
![](/img/style/loading.gif)